|
Author | Pts | Biological predictors/prognosticators | Correlations | p |
|
Michalides et al. [28] | 198 | MDM2, MTBP, p53, and HNSCC OS* | Low MDM2 versus high MDM2 | 0.248 |
P53+ AND low MDM2 versus other status | 0.035 |
|
Poeta et al. [29] | 53 | P53 and RR after P-based NACT | 4/15 CR versus 20/38 NR | 0.12 |
|
Nakashima et al. [24] | 76 | P53, MDM2, Rb, and dysplasia | HNSCC | P53 66% MDM2 46% |
Hyperplastic lesions | P53 55% MDM2 31% |
Dysplastic lesion | P53 64% MDM2 44% |
|
Hamid et al. [27] | 62 | MDM2, p53, HNSCC OS, and stage | P53+ AND low MDM2 | 0.07 |
P53+ AND IHC staining | 0.018 |
MDM2 and T stage | 0.10 |
MDM2 and T4 versus T1 | 0.015 |
Low MDM2 and 3 y OS | 0.034 |
|
Chen et al. [34] | 660** | MDM2 polymorphism and HPV 16 seropositivity | MDM2-rs2279744 TT versus GT | |
MDM2-rs2279744 TT versus GG | |
MDM2-rs2279744 TT versus GT/GG | |
MDM2-rs2279744 TT versus AG | |
MDM2-rs2279744 TT versus AG/GG | |
|
Gasco and Crook [17] | 2073*** | MDM2, p53, and HNSCC onset | MDM2 SNP309 | 0.638 |
MDM2 A2164G | 0.580 |
P53 codon 72 | 0.193 |
|
Agarwal et al. [38] | 128**** | MDM2, p53, and prognosis | MDM2 mut/p53+ AND stage III/IV | 0.0009 |
MDM2 mut/p53+ AND N+ | 0.0325 |
|
Sullivan et al. [20] | 73 | p53 and OS | P53 72R versus p53 72P | 0.007 |
wt p53 (72R or 72P) versus no wt P53 | 0.0001 |
P53 72R versus p53 72P + 72R | 0.02 |
|
Bergamaschi et al. [5] | 70 | p53, p73, OS, and response | CR: p53 wt versus no wt P53 | 0.0001 |
PFS: p53 wt versus no wt P53 | 0.0007 |
PFS: p53 72R versus 72P | 0.008 |
OS: p53 72R versus 72P | 0.0044 |
PFS: p73−/p53+ versus p73+/p53+ | 0.05 |
|
Hamid et al. [27] | 420 | p53 and OS | p53+ versus p53− | 0.074 |
p53+ disruptive versus p53+ nondisruptive | 0.001 |
|
|